Teva
NYSE:TEVAPharmaPetah Tikva, Israel, Israel · Est. 1901 · 43,000 employees
Teva Pharmaceutical Industries is a global pharmaceutical company that develops, manufactures, and distributes generic and specialty medicines.
7
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
7
Indications↗
Distinct diseases across all programs
433
Clinical Trials↗
All sponsored trials (all statuses)
86
Orange Book Patents
Across 6 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
7 drugs in development
Phase 31
Phase 24
Phase 12
Preclinical1
By Therapeutic Area
top 6
Gastroenterology
338%
Respiratory
113%
Neurology
113%
Dermatology
113%
Oncology
113%
Infectious Disease
113%
R&D Momentum
44/100
Pipeline Velocity
11/100
Trial Completion Rate
88/100
Pipeline Concentration
22/100
Pipeline Freshness
70/100
Strategic Signals
- ↗Early-stage heavy pipeline may seek late-stage partners
- ↗Active in Respiratory but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Sep 15, 2026
Recruiting
An Open-Label Extension, Multi-Centered, Phase 2 Trial to Describe the Safety and Efficacy of TEV-56286 (Emrusolmin) in Participants With Multiple System Atrophy
Sep 12, 2026
Active, not recruiting
A Randomized, Double-Blind, Multicenter, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of Fluticasone Propionate/Albuterol Sulfate Fixed-Dose Combination on Severe Asthma Exacerbations in Patients With Asthma
Sep 9, 2026
Recruiting
A Phase 1 Double-Blind, Randomized, Placebo-Controlled, Single and Multiple Escalating Dose Trial in Healthy Participants to Assess Pharmacokinetics, Safety, and Tolerability of TEV-56286 at Clinical and Supratherapeutic Doses
Earlier
Sep 1, 2026TrialA 4-Week, Double-Blind, Placebo-Controlled, Parallel-Group, Efficacy and Safety Trial of Fluticasone Propionate/Albuterol Sulfate Combination Compared to Fluticasone Propionate, Albuterol Sulfate or Placebo Delivered by Multidose Dry Powder Inhaler in Participants 12 Years and Older With Asthma
Aug 28, 2026TrialReal-World Effectiveness and Safety of Deutetrabenazine in Chinese Patients With Chorea Associated With Huntington's Disease.
Aug 27, 2026TrialA Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 2a Trial to Characterize the Efficacy and Safety of TEV-53408 in Adults With Celiac Disease While Undergoing Oral Gluten Exposure
Aug 8, 2026TrialA Phase 1 Open-Label Mass Balance Clinical Trial to Investigate the Absorption, Metabolism, and Excretion of Single Oral Administration of [14C]-TEV-56286 Following Multiple Oral Administrations of Nonlabeled TEV-56286 to Healthy Male Participants
Aug 8, 2026TrialA Phase 2b, Randomized, Double-Blind Long-Term Extension Study to Evaluate Pharmacokinetics, Efficacy, Safety, and Tolerability of TEV-48574 in Adult Patients With Moderate to Severe Ulcerative Colitis or Crohn's Disease Who Completed the Treatment Phase of the Dose-Ranging Study (RELIEVE UCCD LTE)
4 more events
Aug 5, 2026TrialAn Open Label, Single Dose, 3-Period, Crossover Study to Determine the Pharmacokinetic Profile and Safety of Fluticasone Propionate/Albuterol Sulfate (Fp/ABS) Multidose Dry Powder Inhaler With e-Module (eMDPI) Compared to Fluticasone Propionate Multidose Dry Powder Inhaler (Fp MDPI) in Participants With Asthma (4 to 11 Years Old)
Jul 28, 2026TrialFremanezumab (TEV-48125) Compassionate Use Program for Pediatric Patients (6 to 17 Years) With Chronic or Episodic Migraine
Jul 25, 2026TrialA Multicenter, Open-Label Study Evaluating the Long-Term Safety, Tolerability, and Efficacy of Monthly Subcutaneous Administration of Fremanezumab for the Preventive Treatment of Episodic and Chronic Migraine in Pediatric Patients 6 to 17 Years of Age
Jul 21, 2026TrialA Multi-centered, Double-blind, Randomized, Placebo-controlled, Parallel Group Phase 2 Study of TEV-56286 for the Treatment of Patients With Multiple System Atrophy (TOPAS-MSA)
Details
Company Info
Company Overview
$9.5B
Mkt Cap
$15.6B
Revenue
—
Cash
CEOKåre Schultz
Founded1901
Employees43,000
HQPetah Tikva, Israel, Israel
ExchangeNYSE:TEVA
Websitetevapharm.com
LinkedInCompany Page
Therapeutic Focus
NeurologyPsychiatryOncologyCardiovascularMetabolic & EndocrineImmunologyOphthalmologyOtherRespiratoryDermatologyInfectious DiseaseGastroenterologyHematologyMusculoskeletalNephrology
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Neurology
Gastroenterology
Celiac Disease
TEV-53408Phase 2
Crohn Disease
TEV-48574Phase 2
TEV-48574 Dose Regiment BPhase 2
Neurology
Oncology
Regulatory
Regulatory Timeline
20131 event
FDAOct 25
Zohydro Er — ZOHYDRO ER
Application NDA202880 (NDA)
20141 event
FDANov 20
Zohydro Er — HYSINGLA ER
Application NDA206627 (NDA)
20161 event
FDAMar 23
Cinqair — CINQAIR
Application BLA761033 (BLA)
20173 events
FDAApr 3
Austedo — AUSTEDO
Application NDA208082 (NDA)
FDAApr 3
Austedo Xr — AUSTEDO
Application NDA208082 (NDA)
FDAJan 17
Zohydro Er — VANTRELA ER
Application NDA207975 (NDA)
20182 events
FDASep 14
Ajovy — AJOVY
Application BLA761089 (BLA)
FDASep 14
Ajovy — AJOVY
Application BLA761089
20202 events
FDAMar 13
Istodax — ROMIDEPSIN
Application NDA208574 (NDA)
FDAJan 27
Ajovy — AJOVY
Application BLA761089
20211 event
FDASep 24
Ajovy — AJOVY
Application BLA761089
20222 events
FDAJul 27
Taxol — PACLITAXEL
Application NDA211875 (NDA)
FDAJul 27
Taxol — PACLITAXEL
Application NDA211875 (NDA)
20234 events
FDAMay 11
Taxol — PACLITAXEL
Application NDA216338 (NDA)
FDAMay 11
Taxol — PACLITAXEL
Application NDA216338 (NDA)
FDAFeb 17
Austedo — AUSTEDO XR
Application NDA216354 (NDA)
FDAFeb 17
Austedo Xr — AUSTEDO XR
Application NDA216354 (NDA)
20252 events
FDAAug 5
Ajovy — AJOVY
Application BLA761089
FDAMar 21
Ajovy — AJOVY
Application BLA761089
20261 event
FDAJun 5
Ajovy — AJOVY
Application BLA761089
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)